Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer.
abiraterone
apalutamide
cabazitaxel
darolutamide
enzalutamide
radium-223
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Jul 2020
01 Jul 2020
Historique:
received:
06
05
2020
revised:
19
06
2020
accepted:
25
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
8
7
2020
Statut:
epublish
Résumé
Prostate cancer (PC) is the most common male cancer in Western Countries. In recent years, the treatment of relapsed or metastatic disease had benefited by the introduction of a variety of new different drugs. In consideration of the relative long survival of PC patients, side effects of these drugs must be considered and monitored. In this review, we analyzed the newly developed therapies for PC treatment, describing the mechanism of action, the metabolism and latest clinical trials that led to the approval of these drugs in clinical practice. We then evaluated the cardiovascular and renal side effects from pivotal phase III and II studies and meta-analyses. Cardiovascular side effects are the most frequent, in particular hypertension, while renal toxicity is rarer and not well described in literature. Therefore, there is a need to better define the effects of these therapies, in order to personalize patient treatment on the basis of their comorbidities and preferences, in addition to their symptoms and disease load.
Identifiants
pubmed: 32630204
pii: cancers12071750
doi: 10.3390/cancers12071750
pmc: PMC7407336
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
J Clin Oncol. 2017 Oct 1;35(28):3198-3206
pubmed: 28809610
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Ann Nucl Med. 2016 Aug;30(7):453-60
pubmed: 27272279
Cancer Manag Res. 2017 May 16;9:167-178
pubmed: 28553142
Cancer Chemother Pharmacol. 2016 Dec;78(6):1185-1197
pubmed: 27796539
Sci Rep. 2015 Jul 03;5:12007
pubmed: 26137992
Clin Genitourin Cancer. 2018 Oct;16(5):332-340
pubmed: 30197098
Oncologist. 2011;16(2):175-81
pubmed: 21257717
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
JAMA. 2011 Dec 7;306(21):2359-66
pubmed: 22147380
Br J Clin Pharmacol. 2018 Jan;84(1):122-129
pubmed: 28881501
Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):835-46
pubmed: 23581700
Crit Rev Oncol Hematol. 2013 Oct;88(1):75-86
pubmed: 23522920
J Oncol Pharm Pract. 2018 Mar;24(2):143-145
pubmed: 28147927
Oncotarget. 2017 Aug 8;8(48):84572-84578
pubmed: 29137449
BJU Int. 2015 Dec;116(6):880-7
pubmed: 25639506
J Clin Oncol. 2007 Jun 10;25(17):2420-5
pubmed: 17557956
Lancet Oncol. 2015 Feb;16(2):152-60
pubmed: 25601341
Lancet. 2010 Apr 24;375(9724):1437-46
pubmed: 20398925
Biomed Pharmacother. 2018 May;101:211-218
pubmed: 29494958
Clin Genitourin Cancer. 2013 Sep;11(3):238-250.e1
pubmed: 23659772
Clin Pharmacokinet. 2020 Feb;59(2):229-244
pubmed: 31432469
Ann Oncol. 2020 May;31(5):650-658
pubmed: 32321669
Cancers (Basel). 2020 Jan 12;12(1):
pubmed: 31940958
Clin Kidney J. 2014 Feb;7(1):11-22
pubmed: 25859345
J Oncol Pharm Pract. 2019 Dec;25(8):1968-1978
pubmed: 31359832
Eur J Cancer. 2013 Jan;49(1):25-34
pubmed: 22975213
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
BJU Int. 2001 Jun;87(9):821-6
pubmed: 11412219
Clin Med Insights Cardiol. 2019 Jul 29;13:1179546819866445
pubmed: 31384135
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Cancer Chemother Pharmacol. 2018 Sep;82(3):457-468
pubmed: 29974203
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
J Clin Oncol. 2014 Aug 1;32(22):2389-90
pubmed: 24934791
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Expert Rev Anticancer Ther. 2015;15(9):1007-17
pubmed: 26313416
N Engl J Med. 2020 Apr 16;382(16):1557-1563
pubmed: 32294352
Anticancer Drugs. 2015 Mar;26(3):350-8
pubmed: 25462133
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Annu Rev Med. 2019 Jan 27;70:479-499
pubmed: 30691365
Lancet Oncol. 2019 May;20(5):686-700
pubmed: 30987939
P T. 2012 Aug;37(8):440-8
pubmed: 23091336
Lancet Oncol. 2002 Aug;3(8):453
pubmed: 12147423
J Urol. 2015 Nov;194(5):1277-84
pubmed: 26151676
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
JAMA. 2013 Jul 17;310(3):289-96
pubmed: 23860987
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Eur Urol Focus. 2017 Oct;3(4-5):385-394
pubmed: 29128297
Lancet Oncol. 2014 Nov;15(12):1397-406
pubmed: 25439694
Cancer Treat Rev. 2012 May;38(3):235-40
pubmed: 21605937
Clin Cancer Res. 2018 Feb 1;24(3):541-546
pubmed: 29150561
Clin Pharmacokinet. 2016 Nov;55(11):1369-1380
pubmed: 27106175
Clin Pharmacokinet. 2020 Apr 27;:
pubmed: 32338345
Lancet Oncol. 2014 Aug;15(9):975-85
pubmed: 24974051
Sci Rep. 2019 Mar 4;9(1):3392
pubmed: 30833616
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
Eur Urol. 2013 Jun;63(6):977-82
pubmed: 23116658
J Clin Oncol. 1996 Jun;14(6):1756-64
pubmed: 8656243
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
J Clin Endocrinol Metab. 2001 Sep;86(9):4261-7
pubmed: 11549659
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2009 Jan 15;15(2):723-30
pubmed: 19147780
BJU Int. 2010 Aug;106(4):462-9
pubmed: 20346033
Eur Urol. 2014 May;65(5):875-83
pubmed: 24099659
Drugs Aging. 2014 Dec;31(12):873-82
pubmed: 25387443
J Natl Cancer Inst. 2012 Sep 5;104(17):1335-42
pubmed: 22835388
Target Oncol. 2019 Oct;14(5):527-539
pubmed: 31571095
J Clin Oncol. 2006 Sep 20;24(27):4448-56
pubmed: 16983113
Clin Genitourin Cancer. 2018 Jun;16(3):e645-e653
pubmed: 29339044
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712
Cancer Chemother Pharmacol. 2013 Mar;71(3):681-92
pubmed: 23299792